Rayonier Advanced Materials Inc. (RYAM)

Executive Summary / Key Takeaways

• RYAM's 2025 guidance of $135-140 million EBITDA represents a cyclical trough, not structural decline, driven by temporary tariff disruptions, operational setbacks, and paperboard market weakness that mask the underlying durability of its cellulose specialties franchise.
• The company's cellulose specialties business operates in a highly concentrated global oligopoly with 90%+ capacity utilization and no new supply before 2029, positioning RYAM to capture a meaningful price reset in 2026 that could recapture inflation-driven margin erosion from the past decade.
• A portfolio of biomaterial projects offers compelling unit economics with equity ROIs ranging from 1.1x to 7x (for BioNova projects), targeting $31 million of run-rate EBITDA by 2027 through investments that leverage existing infrastructure and require minimal incremental capital.
• Management's $300 million-plus EBITDA target by 2027 hinges on executing $30 million in cost reductions, $20 million in specialty margin enhancement, and stabilizing the Temiscaming paperboard operations, creating a potential valuation inflection if achieved.
• The announced retirement of CEO De Lyle Bloomquist by May 2026 introduces execution risk during a critical transition period, while tariff headwinds and acetate destocking could persist longer than management's base case assumes.

Setting the Scene: A Century-Old Business Undergoing Radical Surgery

Rayonier Advanced Materials, founded in 1926 and headquartered in Jacksonville, Florida, has spent nearly a century building its position as a global leader in cellulose specialties—natural polymers that serve as essential building blocks for everything from LCD screens and pharmaceutical filters to performance additives in food and industrial applications. This legacy business, which generates high-purity cellulose pulp products for demanding applications where consistency and quality command premium pricing, has historically been overshadowed by the company's commodity pulp and paperboard operations.

The current investment story begins with a series of deliberate amputations. In August 2021, RYAM sold its Canadian lumber and newsprint facilities, removing a volatile commodity exposure. In July 2024, the company indefinitely suspended cellulose production at its Temiscaming plant, a move that eliminated high-cost capacity while retaining the site's paperboard and high-yield pulp assets. The first quarter of 2025 brought a final organizational cleaving, splitting the former High Purity Cellulose segment into three distinct businesses: Cellulose Specialties, Biomaterials, and Cellulose Commodities. This restructuring reflects a strategic recognition that RYAM's value lies not in volume-driven commodity production but in specialized, high-margin applications where technical expertise creates defensible moats.

The industry structure reinforces this focus. Global cellulose specialty capacity is concentrated among three producers—RYAM, Borregaard (BRG), and Bracell—who collectively control roughly 80% of supply. Industry utilization hovers around 90% and is expected to tighten further, with no major capacity additions anticipated before 2029. This tight supply backdrop coincides with steady demand growth from electronics, pharmaceuticals, and sustainable packaging applications, creating conditions conducive to sustained price increases. Third-party analysts project market growth of approximately 80,000 metric tons over the next two years, a volume expansion that RYAM is uniquely positioned to capture given its outsized share of excess capacity.

Technology, Products, and Strategic Differentiation: The Purity Premium

RYAM's competitive advantage rests on proprietary production processes that deliver cellulose specialties with purity levels and performance characteristics that commodity producers cannot replicate. These high-purity cellulose pulp products serve as essential building blocks in applications where variability is unacceptable—pharmaceutical filters that must meet exacting regulatory standards, LCD displays where optical clarity is paramount, and performance additives where consistency directly impacts end-product quality. This technical differentiation translates into pricing power: RYAM's average sales price per metric ton in cellulose specialties reached $1,873 in Q3 2025, up 7% year-over-year, while EBITDA margins expanded to 32% from 28% despite a 17% volume decline.

The company's vertical integration from timberlands to finished pulp provides a cost structure advantage that becomes particularly valuable during periods of raw material volatility. While specific timberland acreage is not publicly disclosed, RYAM's historical ownership of forest assets and its proximity to wood fiber sources in the U.S. Southeast and Canada create logistical and cost efficiencies that non-integrated competitors like Mercer International (MERC) cannot match. This integration also supports the company's sustainability credentials, with certifications that enable access to environmentally conscious end markets and command green premiums.

The biomaterials strategy represents RYAM's most significant technological pivot. Rather than burning non-cellulose byproducts for energy, the company is converting these streams into high-value products: bioethanol, crude tall oil (CTO), prebiotics, lignosulfonates , and biogenic CO2 for sustainable aviation fuels. The Tartas bioethanol project, operational since early 2024, required only $5-6 million in RYAM equity and is expected to generate $8-10 million in annual EBITDA, representing an annual return of 1.3x to 2x on the equity investment. The Altamaha Green Energy (AGE) project, a 70-megawatt renewable power plant at the Jesup facility, will require $46 million in RYAM equity for a 49% stake but is projected to deliver $50 million in proportional EBITDA, representing an annual return of approximately 1.1x on the equity investment. These projects leverage existing infrastructure, utilities, and site management, making replication prohibitively expensive for competitors and creating a capital-efficient growth vector.

Financial Performance & Segment Dynamics: Trough Year Math

Third quarter 2025 results illustrate the divergent trajectories within RYAM's portfolio. Consolidated revenue fell 12% year-over-year to $353 million, driven by lower sales volumes across all segments and reduced paperboard pricing. Yet operating income improved by $26 million, or 153%, as the absence of prior-year impairment charges, lower fixed costs from the Temiscaming suspension, and an $8 million energy cost benefit more than offset revenue headwinds. This divergence between top-line pressure and bottom-line resilience demonstrates the earnings power of the cost actions and portfolio pruning underway.

Cellulose Specialties, representing the company's core franchise, generated $204 million in sales with $66 million in adjusted EBITDA, achieving a 32% margin that management described as "normalized." The 17% volume decline resulted from accelerated customer purchases in Q4 2024, acetate destocking, and tariff-related order pauses, but the 7% price increase and margin expansion confirm the segment's structural pricing power. Management is pursuing a "meaningful reset" for 2026 pricing to recapture inflation-driven margin erosion, citing that costs have risen 35% faster than pricing since 2014. With industry capacity constrained and RYAM holding most excess supply, the conditions favor successful implementation.

Biomaterials remains in its infancy, with Q3 sales of $8 million and EBITDA of just $1 million, but the pipeline is compelling. The BioNova joint venture with SWEN Capital is advancing four projects requiring approximately $110 million in total investment, projected to generate $39 million in annual EBITDA with RYAM equity ROIs of 7x. The Fernandina Beach bioethanol project faces permitting headwinds from the city government, but management remains confident in eventual approval, citing community benefits and renewable energy credentials. The prebiotics project received GRAS status in July 2025, with live animal tests showing over two times greater efficacy versus existing additives, positioning it for commercialization in the U.S. poultry and swine feed markets.

Cellulose Commodities and Paperboard represent the company's problem children. The commodities segment posted a $3 million EBITDA loss as 125% Chinese tariffs on U.S.-sourced cellulose disrupted global fluff market dynamics, forcing RYAM to shift production toward viscose and paper pulp grades. The paperboard segment managed only $1 million in EBITDA, down from $11 million in Q3 2024, as a 25% U.S. tariff on EU imports and new domestic capacity pressured both volumes and pricing. High-Yield Pulp fared worse, with a $9 million EBITDA loss driven by Chinese oversupply and shipment timing issues to India.

Corporate costs consumed $14 million in EBITDA during the quarter, but management has identified $10.5 million in annual savings through benefit reductions, automation, and contract terminations, with an additional $4-6 million targeted via AI and automation over the next two to three years. These reductions are essential to achieving the company's 2026 cost targets and demonstrating that the corporate function can scale efficiently as the business mix shifts toward higher-margin specialties.

Outlook, Guidance, and Execution Risk: The Path to $300 Million

Management's guidance has undergone several downward revisions throughout 2025, reflecting the extraordinary headwinds the company has faced. The current full-year EBITDA range of $135-140 million implies a second-half trajectory that is improving sequentially, with Q4 expected to benefit from working capital release and normalized order patterns. The company frames 2025 as a "trough year" and Q2 as the "trough quarter," suggesting that the worst impacts from tariffs, operational disruptions, and environmental charges are largely behind it.

The 2026 bridge to recovery rests on three pillars. First, $30 million in cost reductions from the Temiscaming suspension, strategic capital investments, and corporate restructuring. Second, $20 million in specialty margin enhancement through organic growth and the substitution of specialty volumes for commodity sales, driven by RYAM's outsized share of excess industry capacity. Third, $5 million from requalifying Temiscaming cellulose specialty volumes at other facilities, with two customers already qualified and a third expected by year-end. These initiatives collectively target $55 million in incremental EBITDA, though execution risk is elevated given the CEO transition.

The 2027 target of $300 million-plus run-rate EBITDA incorporates the biomaterials portfolio adding $31 million in proportional EBITDA. The AGE project is scheduled for a final investment decision in late 2025, with completion expected in late 2028. BioNova projects are advancing toward final investment decisions in 2025 and early 2026. The European ethers market presents additional upside not included in management's base case; demand declined 110,000 metric tons between 2022 and 2023, but Tartas holds 20,000 metric tons of excess ethers capacity that could generate $15 million in incremental EBITDA if recovery occurs.

The retirement announcement of CEO De Lyle Bloomquist by May 2026 introduces significant execution risk. Bloomquist has spearheaded the portfolio transformation and biomaterials strategy, and his departure during a critical transition phase could disrupt momentum. While the board will likely promote from within, maintaining strategic continuity while navigating tariff mitigation, cost reduction, and project execution will test leadership depth.

Risks and Asymmetries: What Could Break the Thesis

The most material risk to the investment case is that tariff headwinds prove more durable than management's base case assumes. While Chinese tariffs on cellulose specialties have been resolved, retaliatory measures could resurface, particularly if geopolitical tensions escalate. The commodities segment faces direct exposure to Chinese trade policy, and paperboard's 25% U.S. tariff creates a $35-42 million annualized EBITDA headwind that may prove difficult to fully mitigate through domestic sales shifts. Management's plan to replace 105,000 metric tons of U.S. paperboard exports with Canadian domestic sales relies on "buy Canadian" sentiment and trade balance dynamics that may not materialize as quickly as hoped.

Acetate destocking represents another potential drag. While management believes the destocking process will expedite market rebalancing, customers could extend inventory reductions beyond current timelines, particularly if end-market demand for acetate-based products remains soft. This would pressure volumes in the cellulose specialties segment, offsetting pricing gains and delaying margin recovery.

On the upside, several catalysts could drive results above management's conservative projections. The U.S. International Trade Commission's preliminary affirmative injury determination against Brazilian and Norwegian dissolving pulp imports could lead to duties that tighten global supply and support higher pricing. Georgia-Pacific's Memphis facility closure, which produced 10,000-20,000 metric tons of cotton linter pulp grades, creates a volume opportunity that RYAM's excess capacity is well-positioned to capture. The European ethers market recovery could deliver $15 million in incremental EBITDA that is not currently modeled.

The biomaterials portfolio offers asymmetric returns. The Fernandina Beach bioethanol project, despite city permitting delays, could generate $19 million in annual EBITDA for just $6 million in RYAM equity if approved, representing an annual return of over 3x on the equity investment. The AGE project's $50 million proportional EBITDA from $46 million in equity represents an annual return of approximately 1.1x, secured by a 30-year fixed-price power purchase agreement with Georgia Power, creating a stable cash flow stream that would diversify earnings away from cyclical pulp markets.

Valuation Context: Pricing a Transformation

At $5.95 per share, RYAM carries a market capitalization of $398 million and an enterprise value of $1.14 billion, reflecting a net debt position of approximately $742 million. The stock trades at 0.27 times trailing sales and 8.22 times 2025 guided EBITDA, a multiple that appears depressed relative to the company's historical trading range and peer valuations.

Comparing RYAM to its direct competitors reveals a mixed picture. Mercer International trades at 0.07 times sales and 16.14 times EBITDA, reflecting its deeper distress and negative operating margins. Suzano (SUZ) commands 1.19 times sales and 6.20 times EBITDA, benefiting from its scale, cost leadership, and positive growth trajectory. Mativ Holdings (MATV) trades at 0.35 times sales and 9.66 times EBITDA, while Clearwater Paper (CLW) trades at 0.19 times sales and 7.01 times EBITDA. RYAM's valuation sits at the lower end of the peer range on a sales basis but at a premium on EBITDA, reflecting its current margin pressure but also the market's skepticism about its turnaround prospects.

The balance sheet presents both constraints and optionality. Net secured leverage of 4.1 times covenant EBITDA sits within the 5.0 times covenant threshold but limits financial flexibility. Liquidity of $140 million (cash plus ABL availability) provides a runway to execute the transformation, but the company must generate free cash flow to fund its biomaterials equity commitments, including $46 million for AGE. Management's plan to refinance term debt in 2026, when it becomes callable with a 2% premium, could reduce interest expense by over $40 million annually if combined with debt paydown from a potential Temiscaming divestiture.

The valuation calculus hinges entirely on the credibility of the 2027 EBITDA target. If RYAM achieves $300 million in run-rate EBITDA, the stock would trade at approximately 3.8 times forward EBITDA, a multiple that would likely compress as the biomaterials portfolio comes online and the cellulose specialties price reset materializes. Conversely, if the company stalls at $200 million EBITDA, the current valuation offers little margin of safety given the leverage and cyclical exposure.

Conclusion: A Trough Year or a Broken Story?

RYAM's investment case rests on a simple but unproven proposition: that 2025 represents a cyclical trough from which a transformed, higher-margin business will emerge. The evidence for this thesis is compelling but incomplete. The cellulose specialties segment's 32% EBITDA margins, 90%+ industry utilization, and concentrated competitive structure create a durable moat that should enable the company to recapture inflation-driven margin losses through 2026 pricing actions. The biomaterials portfolio offers capital-efficient growth with equity ROIs that are virtually unmatched in the materials sector.

Yet significant execution risks loom. The CEO transition creates uncertainty during a critical phase of cost reduction and market repositioning. Tariff headwinds, while potentially temporary, are eroding $85 million in annual revenue and may persist longer than management's optimistic base case. The paperboard and high-yield pulp segments, which remain profitable in normal conditions, are currently generating substantial losses that offset specialty gains.

For investors, the decision boils down to confidence in management's ability to deliver the $300 million EBITDA target by 2027. If achieved, the stock offers substantial upside from current levels, as the market is pricing in a permanent impairment of earnings power rather than a temporary cyclical trough. If missed, elevated leverage and ongoing commodity exposure could pressure the stock further. The next twelve months will be decisive: successful 2026 price resets, progress on biomaterials final investment decisions, and stabilization of the Temiscaming operations will determine whether RYAM emerges as a leaner, more profitable company or remains mired in structural decline.